Skip header and navigation

Refine By

24 records – page 1 of 3.

4th Scandinavian Symposium on Radiolabeled Monoclonal Antibodies in Diagnosis and Therapy of Cancer. Lillehammer, Norway, January 15-17, 1995.

https://arctichealth.org/en/permalink/ahliterature22942
Source
Acta Oncol. 1996;35(3):257-390
Publication Type
Conference/Meeting Material
Article
Date
1996

The academic global virtual concept in clinical cancer research and its application to breast cancer: The Breast Cancer International Research Group.

https://arctichealth.org/en/permalink/ahliterature20949
Source
Semin Oncol. 1999 Jun;26(3 Suppl 8):4-8
Publication Type
Article
Date
Jun-1999
Author
J M Nabholtz
M A Lindsay
J. Hugh
J. Mackey
M. Smylie
H J Au
K. Tonkin
M. Allen
Author Affiliation
Northern Alberta Breast Cancer Program, Cross Cancer Institute, Edmonton, Canada.
Source
Semin Oncol. 1999 Jun;26(3 Suppl 8):4-8
Date
Jun-1999
Language
English
Publication Type
Article
Keywords
Academic Medical Centers
Antineoplastic Agents - therapeutic use
Breast Neoplasms - drug therapy
Clinical Trials
Drug Industry
Humans
Interprofessional Relations
Medical Oncology - trends
Research
Research Support, Non-U.S. Gov't
Abstract
In contrast to previous decades, the 1990s have witnessed an increase of new agents with significant activity in breast cancer, including chemotherapy, hormone therapy, and, more recently, biologic modifiers. All information appears to confirm that such a trend will persist and even accelerate in the coming decades. Unless clear strategies of development for new drugs are strictly followed, it will become difficult to adequately assess the many new agents with potentially important activity against breast cancer, and patient access may become a limiting key factor. The academic, global virtual concept is calling for the definition of a new relationship between the pharmaceutical industry and clinical researchers. The main aspect is related to the creation of partnerships with an academically controlled global strategy of development for promising new agents, in which the quality and independence of processes (adjuvant setting, for example) are critical. The means are based on the globalization of patient access (worldwide network) and the virtuality of the approach (modern means of communication as well as access to subgroups of patients). The Breast Cancer International Research Group is the first academic global virtual cooperative group in breast cancer and is making contributions in the development of new drugs, such as taxanes, new antiestrogens, and new cytokines.
PubMed ID
10403467 View in PubMed
Less detail

[A glance into the future (the outlook for pediatric oncology)].

https://arctichealth.org/en/permalink/ahliterature216642
Source
Vopr Onkol. 1995;41(2):71-3
Publication Type
Article
Date
1995

[Cancer therapy is still dominated by surgery. It will be a long time before vaccines and new drugs are available]

https://arctichealth.org/en/permalink/ahliterature20812
Source
Lakartidningen. 1999 Sep 1;96(35):3636-7
Publication Type
Article
Date
Sep-1-1999
Author
P. Naredi
Author Affiliation
Kirurgiska kliniken, Norrlands Universitetssjukhus, Umeå.
Source
Lakartidningen. 1999 Sep 1;96(35):3636-7
Date
Sep-1-1999
Language
Swedish
Publication Type
Article
Keywords
Humans
Medical Oncology - trends
Neoplasms - drug therapy - prevention & control - surgery
Surgical Procedures, Operative - methods - trends
Sweden
United States
PubMed ID
10492564 View in PubMed
Less detail

The changing face of Russian oncology.

https://arctichealth.org/en/permalink/ahliterature190898
Source
Lancet Oncol. 2001 Apr;2(4):243-7
Publication Type
Article
Date
Apr-2001
Author
S. Silver
Author Affiliation
susan.silver@lancet.com
Source
Lancet Oncol. 2001 Apr;2(4):243-7
Date
Apr-2001
Language
English
Publication Type
Article
Keywords
Clinical Trials as Topic
Humans
Medical Oncology - trends
Neoplasms - epidemiology - therapy
Russia
Notes
Comment In: Lancet Oncol. 2001 May;2(5):25911905778
PubMed ID
11905772 View in PubMed
Less detail

[Conducting scientific research on the problem "Malignant neoplasms" in the RSFSR].

https://arctichealth.org/en/permalink/ahliterature239691
Source
Sov Med. 1985;(11):71-5
Publication Type
Article
Date
1985

DBCG: the Danish Breast Cancer Cooperative Group--a 30-year struggle for better breast cancer treatment in Denmark.

https://arctichealth.org/en/permalink/ahliterature93220
Source
Acta Oncol. 2008;47(4):491-6
Publication Type
Article
Date
2008

[Development of the oncology service in the Ukrainian SSR]

https://arctichealth.org/en/permalink/ahliterature27102
Source
Vopr Onkol. 1982;28(10):3-8
Publication Type
Article
Date
1982

Developments in the treatment of cancer pain in Finland: the third nation-wide survey.

https://arctichealth.org/en/permalink/ahliterature208847
Source
Pain. 1997 Apr;70(2-3):175-83
Publication Type
Article
Date
Apr-1997
Author
V. Kaasalainen
A. Vainio
T. Ali-Melkkilä
Author Affiliation
Department of Oncology, Helsinki University Hospital, Finland.
Source
Pain. 1997 Apr;70(2-3):175-83
Date
Apr-1997
Language
English
Publication Type
Article
Keywords
Data Collection
Drug Prescriptions
Finland
Humans
Medical Oncology - trends
Palliative Care - trends
Patient Education as Topic
Questionnaires
Social Support
Substance-Related Disorders - etiology
Abstract
This survey was designed to investigate the current status of the management of cancer pain in Finland. In 1995 a questionnaire was randomly sent to 5% (n = 546) of Finnish physicians, excluding specialists not expected to treat cancer patients. Two previous surveys, using the same questionnaire, were conducted in 1985 and 1990 by Vainio. The response rate was 53%. Seventy-nine percent of the respondents treated one or less than one cancer patient a week. Sixty-seven percent of them assessed the severity of cancer pain in their patients as being at least moderate. In 10 years, the proportion of physicians suggesting the WHO analgesic ladder principle to their 'typical cancer patient' had increased from 12% to 28%. At the same time, the suggestions of 'analgesic' without definition had decreased from 48% to 6%. Three simulated patient cases were presented. The mean daily dose of opioids suggested for severe terminal cancer pain corresponded to 72 (18-300) mg of intramuscular morphine in 1995, being only 39 (1-77) mg in 1985 for the same simulated patient case. Continuous infusion of opioid was recommended by 59% of the respondents. Non-steroidal anti-inflammatory drugs as the treatment of choice for bone metastases pain in a patient with breast cancer, was recommended by 68% of the respondents. In the case of local severe pain due to recurrent rectal cancer, 63% of the physicians suggested anaesthetic intervention. Insufficient pain relief and lack of experience were the most common difficulties in pain management. Only one-third of the physicians thought that they had enough time and ability to give sufficient psychological support to their patients.
PubMed ID
9150291 View in PubMed
Less detail

24 records – page 1 of 3.